All In Biotech

Drug Trial Radar · NCT07136779

First-in-Human Trial of VBC101 in Participants With Advanced Solid Tumor Malignancies

PHASE 1/2A OPEN-LABEL CLINICAL TRIAL EVALUATING VBC101, AN EGFR AND CMET TARGETED BI-SPECIFIC ANTIBODY DRUG CONJUGATE, IN PARTICIPANTS WITH ADVANCED SOLID TUMOR MALIGNANCIES

Last checked: Nov 19, 2026Latest source record: Sep 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

310

Planned (sponsor's estimate)

Start

Sep 23, 2025

Primary completion

Jul 1, 2027

Study completion Jul 1, 2028

Sponsor

Lead sponsor
VelaVigo Bio IncIndustry
Sponsor type
Industry
First posted
Aug 22, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, open-label, multiple-dose, FIH Phase 1/2a trial. The Phase 1 portion adopts an accelerated titration for the first dose level, followed by BOIN design to identify the MTD and/or RP2D with potential backfill cohorts. The Phase 2a portion consists of dose optimization followed by cohort expansion to confirm safety and tolerability and to further evaluate the efficacy of the selected RP2D in selected solid tumor malignancies for VBC101.

Conditions

  • Participants With Advanced Solid Tumor Malignancies

Interventions

  • VBC101Drug

    VBC101

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of dose-limiting toxicities (DLT) as defined in the protocolTime frame: (DLT)From time of first dose of VBC101 to end of DLT period (approximately 21 days)
  2. Incidence of Serious Adverse EventsTime frame: From time of Informed Consent to 30 days post last dose of VBC101
  3. Incidence of Adverse Events(AEs)Time frame: From time of Informed Consent to 30 days post last dose of VBC101

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Start Midwest

    Grand Rapids, Michigan · Recruiting

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • NEXT Oncology

    San Antonio, Texas · Recruiting

  • START Mountain Region, LLC.

    West Valley City, Utah · Recruiting

  • NEXT Virginia

    Fairfax, Virginia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.